Vitamin D as a Principal Factor in Mediating Rheumatoid Arthritis-Derived Immune Response

Muhammad M Aslam, Peter John, Attya Bhatti, Sidrah Jahangir, M I Kamboh, Muhammad M Aslam, Peter John, Attya Bhatti, Sidrah Jahangir, M I Kamboh

Abstract

Rheumatoid arthritis (RA) is a systemic multifactorial autoimmune disorder. The interactions between diverse environmental and genetic factors lead to the onset of this complex autoimmune disorder. Serum levels of vitamin D (VD) are involved in the regulation of various immune responses. Vitamin D is a key signaling molecule in the human body that maintains calcium as well as phosphate homeostasis. It also regulates the functions of the immune system and, thus, can play a substantial role in the etiology of various autoimmune disorders, including RA. Low serum VD levels have been found to be associated with a higher risk of RA, although this finding has not been replicated consistently. The molecular mechanisms by which VD influences autoimmunity need to be further explored to understand how variation in plasma VD levels could affect the pathogenesis of RA. This mini-review focuses on the influence of VD and its serum levels on RA susceptibility, RA-associated complexities, treatment, and transcriptome products of key proinflammatory cytokines, along with other cytokines that are key regulators of inflammation in rheumatoid joints.

Figures

Figure 1
Figure 1
Route map of vitamin D from production to action.

References

    1. Gregersen P. K., Amos C. I ., Lee A. T., Lu Y., et al. REL, a member of the NF-κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nature Genetics. 2009;41(7):820–823. doi: 10.1038/ng.395.
    1. Kurreeman F. A., Padyukov L., Marques R. B., et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Medicine. 2007;4(12):p. e358. doi: 10.1371/journal.pmed.0040358.
    1. Firestein G. S. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–361. doi: 10.1038/nature01661.
    1. Zhu H., Deng F. Y., Mo X. B., Qiu Y. H., Lei S. F. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. Pharmacogenomics. 2014;15:551–566.
    1. Joshi V. Arthritis in the elderly. Journal of the Indian Medical Association. 2003;101:408–412.
    1. Simonsson M., Bergman S., Jacobsson L. T. H., Petersson I. F., Svensson B. The prevalence of rheumatoid arthritis in Sweden. Scandinavian Journal of Rheumatology. 1999;28(6):340–343. doi: 10.1080/03009749950155319.
    1. Myasoedova E., Crowson C. S., Kremers H. M., Therneau T. M., Gabriel S. E. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis & Rheumatology. 2010;62(6):1576–1582. doi: 10.1002/art.27425.
    1. Kiadaliri A. A., Felson D. T., Neogi T., Englund M. Brief report: rheumatoid arthritis as the underlying cause of death in thirty-one countries, 1987–2011: trend analysis of world health organization mortality database. Arthritis & Rheumatology. 2017;69(8):1560–1565. doi: 10.1002/art.40091.
    1. Raychaudhuri S. Recent advances in the genetics of rheumatoid arthritis. Current Opinion in Rheumatology. 2010;22(2):109–118. doi: 10.1097/BOR.0b013e328336474d.
    1. Mulcahy B., Frank W.-L., Michael F. M., et al. Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. American Journal of Human Genetics. 1996;59:p. 676.
    1. Georgopoulos S., Plows D., Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. Journal of Inflammation. 1996;46(2):86–97.
    1. Kim G. W., Lee N. R., Pi R. H. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Archives of Pharmacal Research. 2015;38(5):575–584. doi: 10.1007/s12272-015-0569-8.
    1. Brennan F. M., McInnes I. B. Evidence that cytokines play a role in rheumatoid arthritis. The Journal of Clinical Investigation. 2008;118(11):3537–3545. doi: 10.1172/JCI36389.
    1. Lacki J. K., Moser R., Korczowska I., Mackiewicz S., Muller W. TNF-α gene polymorphism does not affect the clinical and radiological outcome of rheumatoid arthritis. Rheumatology International. 2000;19(4):137–140. doi: 10.1007/s002960050117.
    1. Trifunovic Cvetkovic J., Wållberg-Jonsson S., Stegmayr B., Rantapää-Dahlqvist S., Lefvert A. K. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes. The Journal of Rheumatology. 2002;29(2):212–219.
    1. Ferrari S. L., Ahn-Luong L., Garnero P., Humphries S. E., Greenspan S. L. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. The Journal of Clinical Endocrinology & Metabolism. 2003;88(1):255–259. doi: 10.1210/jc.2002-020092.
    1. Jerrard-Dunne P., Sitzer M., Risley P., et al. Interleukin-6 promoter polymorphism modulates the effects of heavy alcohol consumption on early carotid artery atherosclerosis: the carotid atherosclerosis progression study (CAPS) Stroke. 2003;34(2):402–407. doi: 10.1161/01.str.0000053849.09308.b2.
    1. Holick M. F. Vitamin D deficiency. The New England Journal of Medicine. 2007;357(3):266–281. doi: 10.1056/NEJMra070553.
    1. Pérez-López F. R. Vitamin D: The secosteroid hormone and human reproduction. Gynecological Endocrinology. 2007;23(1):13–24. doi: 10.1080/09513590601045629.
    1. Holick M. F. Vitamin D: a millenium perspective. Journal of Cellular Biochemistry. 2003;88(2):296–307. doi: 10.1002/jcb.10338.
    1. Wolpowitz D., Gilchrest B. A. The vitamin D questions: How much do you need and how should you get it? Journal of the American Academy of Dermatology. 2006;54(2):301–317. doi: 10.1016/j.jaad.2005.11.1057.
    1. Audran M., Briot K. Critical reappraisal of vitamin D deficiency. Joint Bone Spine. 2010;77(2):115–119. doi: 10.1016/j.jbspin.2009.12.003.
    1. Souberbielle J.-C., Friedlander G., Kahan A., Cormier C. Evaluating vitamin D status. Implications for preventing and managing osteoporosis and other chronic diseases. Joint Bone Spine. 2006;73(3):249–253. doi: 10.1016/j.jbspin.2006.01.003.
    1. Holick M. F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. American Journal of Clinical Nutrition. 2004;80(6):1678S–1688S. doi: 10.1093/ajcn/80.6.1678S.
    1. Norman A. W. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. American Journal of Clinical Nutrition. 2008;88(2):491S–499S. doi: 10.1093/ajcn/88.2.491S.
    1. DeLuca H. F. Overview of general physiologic features and functions of vitamin D. American Journal of Clinical Nutrition. 2004;80(6):1689S–1696S. doi: 10.1093/ajcn/80.6.1689S.
    1. Bikle D. Nonclassic actions of vitamin D. The Journal of Clinical Endocrinology & Metabolism. 2009;94:26–34.
    1. Holick M. F. Vitamin D: extraskeletal health. Rheumatic Disease Clinics of North America. 2012;38(1):141–160. doi: 10.1016/j.rdc.2012.03.013.
    1. Hossein-nezhad A., Holick M. F. Optimize dietary intake of vitamin D: an epigenetic perspective. Current Opinion in Clinical Nutrition and Metabolic Care. 2012;15:567–579.
    1. Smit E., Crespo C. J., Michael Y., et al. The effect of vitamin D and frailty on mortality among non—institutionalized US older adults. European Journal of Clinical Nutrition. 2012;66(9):1024–1028. doi: 10.1038/ejcn.2012.67.
    1. Holick M. F. Nutrition: D-iabetes and D-eath D-efying vitamin D. Nature Reviews Endocrinology. 2012;8(7):388–390. doi: 10.1038/nrendo.2012.84.
    1. Hossein-nezhad A., Holick M. F. Vitamin D for health: a global perspective. Mayo Clinic Proceedings. 2013;88:720–755.
    1. Jiang X., Kiel D. P., Kraft P. The genetics of vitamin D. Bone. 2018
    1. Arnson Y., Amital H., Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Annals of the Rheumatic Diseases. 2007;66(9):1137–1142. doi: 10.1136/ard.2007.069831.
    1. Carlberg C., Seuter S., de Mello V. D. F., et al. Primary vitamin D target genes allow a categorization of possible benefits of vitamin D 3 supplementation. PLoS ONE. 2013;8(7) doi: 10.1371/journal.pone.0071042.e71042
    1. Cândido F. G., Bressan J. Vitamin D: Link between osteoporosis, obesity, and diabetes? International Journal of Molecular Sciences. 2014;15(4):6569–6591. doi: 10.3390/ijms15046569.
    1. Mosaad Y. M., Hammad E. M., Fawzy Z., et al. Vitamin D receptor gene polymorphism as possible risk factor in rheumatoid arthritis and rheumatoid related osteoporosis. Human Immunology. 2014;75(5):452–461. doi: 10.1016/j.humimm.2014.02.009.
    1. Hussien Y. M., Shehata A., Karam R. A., Alzahrani S. S., Magdy H., El-Shafey A. M. Polymorphism in vitamin D receptor and osteoprotegerin genes in Egyptian rheumatoid arthritis patients with and without osteoporosis. Molecular Biology Reports. 2013;40(5):3675–3680. doi: 10.1007/s11033-012-2443-9.
    1. Tizaoui K., Kaabachi W., Ouled Salah M., Ben Amor A., Hamzaoui A., Hamzaoui K. Vitamin D receptor TaqI and ApaI polymorphisms: a comparative study in patients with Behçet's disease and Rheumatoid arthritis in Tunisian population. Cellular Immunology. 2014;290(1):66–71. doi: 10.1016/j.cellimm.2014.05.002.
    1. Tizaoui K., Hamzaoui K. Association between VDR polymorphisms and rheumatoid arthritis disease: Systematic review and updated meta-analysis of case-control studies. Immunobiology. 2015;220(6):807–816. doi: 10.1016/j.imbio.2014.12.013.
    1. Bhalla A. K., Amento E. P., Clemens T. L., Holick M. F., Krane S. M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. The Journal of Clinical Endocrinology & Metabolism. 1983;57(6):1308–1310. doi: 10.1210/jcem-57-6-1308.
    1. Provvedini D. M., Tsoukas C. D., Deftos L. J., Manolagas S. C. 1,25-Dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983;221(4616):1181–1183. doi: 10.1126/science.6310748.
    1. Cantorna M. T., Mahon B. D. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Experimental Biology and Medicine (Maywood) 2004;229:1136–1142.
    1. Schwalfenberg G. K. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Molecular Nutrition & Food Research. 2011;55(1):96–108. doi: 10.1002/mnfr.201000174.
    1. Cantorna M. T. Mechanisms underlying the effect of vitamin D on the immune system. Proceedings of the Nutrition Society. 2010;69(3):286–289. doi: 10.1017/S0029665110001722.
    1. Higgins M. J., Mackie S. L., Thalayasingam N., Bingham S. J., Hamilton J., Kelly C. A. The effect of vitamin D levels on the assessment of disease activity in rheumatoid arthritis. Clinical Rheumatology. 2013;32(6):863–867. doi: 10.1007/s10067-013-2174-x.
    1. Heidari B., Hajian-Tilaki K., Heidari P. The status of serum vitamin D in patients with rheumatoid arthritis and undifferentiated inflammatory arthritis compared with controls. Rheumatology International. 2012;32(4):991–995. doi: 10.1007/s00296-010-1736-3.
    1. Ritterhouse L. L., Crowe S. R., Niewold T. B., et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Annals of Rheumatic Diseases. 2011;70:1569–1574.
    1. Ranganathan P. Genetics of bone loss in rheumatoid arthritis - role of vitamin D receptor polymorphisms. Rheumatology. 2009;48(4):342–346. doi: 10.1093/rheumatology/ken473.
    1. Szekely J. I., Pataki A. Effects of vitamin D on immune disorders with special regard to asthma, COPD and autoimmune diseases: a short review. Expert Review of Respiratory Medicine. 2012;6:683–704.
    1. Luo J., Wen H., Guo H., Cai Q., Li S., Li X. 1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis. BioMed Research International. 2013;2013:9. doi: 10.1155/2013/101805.101805
    1. Villaggio B., Soldano S., Cutolo M. 1,25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages. Clinical and Experimental Rheumatology. 2012;30:934–938.
    1. Christakos S., Dhawan P., Verstuyf A., Verlinden L., Carmeliet G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiological Reviews. 2016;96(1):365–408. doi: 10.1152/physrev.00014.2015.
    1. Bogaczewicz J., Sysa-Jedrzejowska A., Arkuszewska C., et al. Vitamin D status in systemic lupus erythematosus patients and its association with selected clinical and laboratory parameters. Lupus. 2012;21(5):477–484. doi: 10.1177/0961203311427549.
    1. Jones B. J., Twomey P. J. Issues with vitamin D in routine clinical practice. Rheumatology. 2008;47:1267–1268.
    1. Cantorna M. T. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proceedings of the Society for Experimental Biology and Medicine. 2000;223(3):230–233. doi: 10.1046/j.1525-1373.2000.22333.x.
    1. Kamen D. L., Cooper G. S., Bouali H., Shaftman S. R., Hollis B. W., Gilkeson G. S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmunity Reviews. 2006;5(2):114–117. doi: 10.1016/j.autrev.2005.05.009.
    1. Elshabrawy H. A., Chen Z., Volin M. V., Ravella S., Virupannavar S., Shahrara S. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 2015;18(4):433–448. doi: 10.1007/s10456-015-9477-2.
    1. Mateen S., Zafar A., Moin S., Khan A. Q., Zubair S. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clinica Chimica Acta. 2016;455:161–171. doi: 10.1016/j.cca.2016.02.010.
    1. Cantorna M. T., Mahon B. D. D-hormone and the immune system. The Journal of Rheumatology. 2005;76:11–20.
    1. Cantorna M. T., Zhu Y., Froicu M., Wittke A. Vitamin D status, 1, 25-dihydroxyvitamin D3, and the immune system. The American Journal of Clinical Nutrition. 2004;80:1717s–1720s.
    1. Old L. J. Tumor necrosis factor (TNF) Science. 1985;230(4726):630–632. doi: 10.1126/science.2413547.
    1. Edrees A. F., Misra S. N., Abdou N. I. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clinical and Experimental Rheumatology. 2005;23(4):469–474.
    1. Vasanthi P., Nalini G., Rajasekhar G. Role of tumor necrosis factor-alpha in rheumatoid arthritis: a review. International Journal of Rheumatic Diseases. 2007;10(4):270–274. doi: 10.1111/j.1479-8077.2007.00305.x.
    1. Müller K., Bendtzen K. Inhibition of human t lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin d3. Differential effects on CD45RA+ and CD45R0+ cells. Autoimmunity. 1993;14(1):37–43. doi: 10.3109/08916939309077355.
    1. Hakim I., Bar-Shavit Z. Modulation of TNF-α expression in bone marrow macrophages: Involvement of vitamin D response element. Journal of Cellular Biochemistry. 2003;88(5):986–998. doi: 10.1002/jcb.10453.
    1. Gu X., Gu B., Lv X., et al. 1, 25-dihydroxy-vitamin D3 with tumor necrosis factor-alpha protects against rheumatoid arthritis by promoting p53 acetylation-mediated apoptosis via Sirt1 in synoviocytes. Cell Death & Disease. 2016;7(10) doi: 10.1038/cddis.2016.300.e2423
    1. Peterson C. A., Heffernan M. E. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. Journal of Inflammation. 2008;5, article 10 doi: 10.1186/1476-9255-5-10.
    1. Bastard J., Jardel C., Delattre J., Hainque B., Bruckert E., Oberlin F. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation. 1999;99(16):2219c–2222c. doi: 10.1161/circ.99.16.2219/c.
    1. Pedersen B. K. Muscle as a secretory organ. Comprehensive Physiology. 2013 doi: 10.1002/cphy.c120033.
    1. Koch A. E., Kunkel S. L., Strieter R. M. Cytokines in rheumatoid arthritis. Journal of Investigative Medicine. 1995;43(1):28–38.
    1. Arend W. P. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Seminars in Arthritis and Rheumatism. 2001;30(5) supplement 2:1–6. doi: 10.1053/sarh.2001.23693.
    1. Vervoordeldonk M. J. B. M., Tak P. P. Cytokines in rheumatoid arthritis. Current Rheumatology Reports. 2002;4(3):208–217. doi: 10.1007/s11926-002-0067-0.
    1. Brzustewicz E., Bryl E. The role of cytokines in the pathogenesis of rheumatoid arthritis - Practical and potential application of cytokines as biomarkers and targets of personalized therapy. Cytokine. 2015;76(2):527–536. doi: 10.1016/j.cyto.2015.08.260.
    1. Pettipher E. R., Higgs G. A., Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proceedings of the National Acadamy of Sciences of the United States of America. 1986;83(22):8749–8753. doi: 10.1073/pnas.83.22.8749.
    1. Burger D., Dayer J.-M., Palmer G., Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Practice & Research Clinical Rheumatology. 2006;20(5):879–896. doi: 10.1016/j.berh.2006.06.004.
    1. de Castro Kroner J., Sommer A., Fabri M. Vitamin D every day to keep the infection away? Nutrients. 2015;7(6):4170–4188. doi: 10.3390/nu7064170.
    1. Lee B.-N., Kim T.-H., Jun J.-B., et al. Upregulation of interleukin-1β production by 1,25-Dihydroxyvitamin D3 in activated human macrophages. Molecular Biology Reports. 2011;38(3):2193–2201. doi: 10.1007/s11033-010-0348-z.
    1. Villaggio B., Soldano S., Cutolo M. 1,25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages. Clinical and Experimental Rheumatology. 2012;30(6):934–938.
    1. Neve A., Corrado A., Cantatore F. P. Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis. Clinical and Experimental Medicine. 2014;14(3):275–283. doi: 10.1007/s10238-013-0249-2.
    1. Kong J., Grando S. A., Li Y. C. Regulation of IL-1 family cytokines IL-1α, IL-1 receptor antagonist, and IL-18 by 1,25-Dihydroxyvitamin D3 in primary keratinocytes. The Journal of Immunology. 2006;176:p. 3780.
    1. Eklund D., Persson H. L., Larsson M., et al. Vitamin D enhances IL-1beta secretion and restricts growth of mycobacterium tuberculosis in macrophages from TB patients. International Journal of Mycobacteriology. 2013;2:18–25.
    1. Verway M., Bouttier M., Wang T.-T., et al. Vitamin D induces interleukin-1beta expression: paracrine macrophage epithelial signaling controls M. tuberculosis infection. PLoS Pathogens. 2013;9(6) doi: 10.1371/journal.ppat.1003407.e1003407
    1. Inaba M., Yukioka K., Furumitsu Y., et al. Positive correlation between levels of IL-1 or IL-2 and 1,25(OH)2D/25-OH-D ratio in synovial fluid of patients with rheumatoid arthritis. Life Sciences. 1997;61(10):977–985. doi: 10.1016/S0024-3205(97)00602-4.
    1. Di Rosa M., Malaguarnera G., De Gregorio C., Palumbo M., Nunnari G., Malaguarnera L. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cellular Immunology. 2012;280(1):36–43. doi: 10.1016/j.cellimm.2012.10.009.
    1. Nishimoto N., Kishimoto T. Interleukin 6: from bench to bedside. Nature Clinical Practice Rheumatology. 2006;2(11):619–626. doi: 10.1038/ncprheum0338.
    1. Lipsky P. E. Interleukin-6 and rheumatic diseases. Arthritis Research and Therapy. 2006;8:p. S4.
    1. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86(4):1243–1254.
    1. Taga T., Hibi M., Hirata Y., et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58(3):573–581. doi: 10.1016/0092-8674(89)90438-8.
    1. Desgeorges A., et al. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. The Journal of Rheumatology. 1997;24:1510–1516.
    1. O'Shea J. J., Murray P. J. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28(4):477–487. doi: 10.1016/j.immuni.2008.03.002.
    1. Hirano T. Cytokines in autoimmune disease and chronic inflammatory proliferative disease. Cytokine & Growth Factor Reviews. 2002;13(4-5):297–298. doi: 10.1016/S1359-6101(02)00017-5.
    1. Prowse K. R., Baumann H. Interleukin-1 and interleukin-6 stimulate acute-phase protein production in primary mouse hepatocytes. Journal of Leukocyte Biology. 1989;45(1):55–61. doi: 10.1002/jlb.45.1.55.
    1. Houssiau F. A., Devogelaer J.-P., van Damme J., de Deuxchaisnes C. N., van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis & Rheumatism. 1988;31(6):784–788. doi: 10.1002/art.1780310614.
    1. Suematsu S., Matsuda T., Aozasa K., et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proceedings of the National Acadamy of Sciences of the United States of America. 1989;86(19):7547–7551. doi: 10.1073/pnas.86.19.7547.
    1. Suzuki M., Hashizume M., Yoshida H., Shiina M., Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. Cytokine. 2010;51(2):178–183. doi: 10.1016/j.cyto.2010.03.017.
    1. Van Snick J. Interleukin-6: an overview. Annual Review of Immunology. 1990;8:253–278. doi: 10.1146/annurev.iy.08.040190.001345.
    1. Zhang Y., Leung D. Y. M., Richers B. N., et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. The Journal of Immunology. 2012;188(5):2127–2135. doi: 10.4049/jimmunol.1102412.
    1. Nonn L., Peng L., Feldman D., Peehl D. M. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Research. 2006;66(8):4516–4524. doi: 10.1158/0008-5472.can-05-3796.
    1. Xue M.-L., Zhu H., Thakur A., Willcox M. 1α,25-Dihydroxyvitamin D3 inhibits pro-inflammatory cytokine and chemokine expression in human corneal epithelial cells colonized with Pseudomonas aeruginosa. Immunology & Cell Biology. 2002;80(4):340–345. doi: 10.1046/j.1440-1711.80.4august.1.x.
    1. Stockinger B. Th17 cells: an orphan with influence. Immunology & Cell Biology. 2007;85(2):83–84. doi: 10.1038/sj.icb.7100035.
    1. Huhtakangas J. A., Veijola J., Turunen S., et al. 1,25(OH)2D3 and calcipotriol, its hypocalcemic analog, exert a long-lasting anti-inflammatory and anti-proliferative effect in synoviocytes cultured from patients with rheumatoid arthritis and osteoarthritis. The Journal of Steroid Biochemistry and Molecular Biology. 2017;173:13–22. doi: 10.1016/j.jsbmb.2017.01.017.
    1. Hemdan N. Y., Birkenmeier G., Wichmann G., et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmunity Reviews. 2010;9(11):785–792. doi: 10.1016/j.autrev.2010.07.003.
    1. van Hamburg J. P., Asmawidjaja P. S., Davelaar N., et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin‐17A production. Arthritis & Rheumatism. 2010;63:73–83.
    1. Ikeda U., Wakita D., Ohkuri T., et al. 1α,25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunology Letters. 2010;134(1):7–16. doi: 10.1016/j.imlet.2010.07.002.
    1. Ranganathan P., Khalatbari S., Yalavarthi S., Marder W., Brook R., Kaplan M. J. Vitamin D deficiency, interleukin 17, and vascular function in rheumatoid arthritis. The Journal of Rheumatology. 2013;40(9):1529–1534. doi: 10.3899/jrheum.130012.
    1. Daniel C., Sartory N. A., Zahn N., Radeke H. H., Stein J. M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. The Journal of Pharmacology and Experimental Therapeutics. 2008;324(1):23–33. doi: 10.1124/jpet.107.127209.
    1. Tang J., Zhou R., Luger D., et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. The Journal of Immunology. 2009;182(8):4624–4632. doi: 10.4049/jimmunol.0801543.
    1. Mora J. R., Iwata M., Von Andrian U. H. Vitamin effects on the immune system: vitamins A and D take centre stage. Nature Reviews Immunology. 2008;8:685–698.
    1. Chang S. H., Chung Y., Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. Journal of Biological Chemistry. 2010;285:38751–38755.
    1. Von Essen M. R., Kongsbak M., Schjerling P., Olgaard K., Ødum N., Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nature Immunology. 2010;11(4):344–349. doi: 10.1038/ni.1851.
    1. Colin E. M., Asmawidjaja P. S., van Hamburg J. P., et al. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis & Rheumatology. 2010;62(1):132–142. doi: 10.1002/art.25043.
    1. Buchan G. S., Barrett K., Fujita T., Taniguchi T., Maini R., Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clinical and Experimental Immunology. 1988;71:295–301.
    1. Takeuchi A., Reddy G. S., Kobayashi T., Okano T., Park J., Sharma S. Nuclear factor of activated T cells (NFAT) as a molecular target for 1a, 25-dihydroxyvitamin D3-mediated effects. Journal of Immunology. 1998;160:209–218.
    1. Lemire J. M., Clay Archer D. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. The Journal of Clinical Investigation. 1991;87(3):1103–1107. doi: 10.1172/JCI115072.
    1. Szodoray P., Nakken B., Gaal J., et al. The complex role of vitamin D in autoimmune diseases. Scandinavian Journal of Immunology. 2008;68(3):261–269. doi: 10.1111/j.1365-3083.2008.02127.x.
    1. Van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. The Journal of Steroid Biochemistry and Molecular Biology. 2005;97(1-2):93–101. doi: 10.1016/j.jsbmb.2005.06.002.
    1. Alroy I., Towers T. L., Freedman L. P. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Molecular and Cellular Biology. 1995;15(10):5789–5799. doi: 10.1128/MCB.15.10.5789.
    1. Cantorna M. T., Hayes C. E., DeLuca H. F. 1,25-dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. Journal of Nutrition. 1998;128(1):68–72. doi: 10.1093/jn/128.1.68.
    1. Correale J., Ysrraelit M. C., Gaitn M. I. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain. 2009;132(5):1146–1160. doi: 10.1093/brain/awp033.
    1. Boonstra A., Barrat F. J., Crain C., Heath V. L., Savelkoul H. F. J., O'Garra A. 1α,25-Dihydroxyvitamin D3 has a direct effect on naive CD4+ T cells to enhance the development of Th2 cells. The Journal of Immunology. 2001;167(9):4974–4980. doi: 10.4049/jimmunol.167.9.4974.
    1. Petrovic-Rackov L., Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clinical Rheumatology. 2006;25:448–452.
    1. Rausch-Fan X., Leutmezer F., Willheim M., et al. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific Th cell clones by 1α,25-dihydroxyvitamin D3. International Archives of Allergy and Immunology. 2002;128(1):33–41. doi: 10.1159/000058001.
    1. D'Ambrosio D., Cippitelli M., Cocciolo M. G., et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-κB downregulation in transcriptional repression of the p40 gene. The Journal of Clinical Investigation. 1998;101(1):252–262. doi: 10.1172/JCI1050.
    1. Penna G., Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. The Journal of Immunology. 2000;164:2405–2411.
    1. Wu H. J., Lo Y., Luk D., Lau C. S., Lu L., Mok M. Y. Alternatively activated dendritic cells derived from systemic lupus erythematosus patients have tolerogenic phenotype and function. Clinical Immunology. 2015;156(1):43–57. doi: 10.1016/j.clim.2014.10.011.
    1. Jeffery L. E., Raza K., Hewison M. Vitamin D in rheumatoid arthritistowards clinical application. Nature Reviews Rheumatology. 2015;12:p. 201.
    1. Zwerina K., Baum W., Axmann R., et al. Vitamin D receptor regulates TNF-mediated arthritis. Annals of the Rheumatic Diseases. 2011;70(6):1122–1129. doi: 10.1136/ard.2010.142331.
    1. Merlino L. A., Curtis J., Mikuls T. R., Cerhan J. R., Criswell L. A., Saag K. G. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa women's health study. Arthritis & Rheumatism. 2004;50:72–77.
    1. Feng X., Lv C., Wang F., Gan K., Zhang M., Tan W. Modulatory effect of 1,25-dihydroxyvitamin D3 on IL1β-induced RANKL, OPG, TNFα, and IL-6 expression in human rheumatoid synoviocyte MH7A. Clinical and Developmental Immunology. 2013;2013:8. doi: 10.1155/2013/160123.160123
    1. Song G. G., Bae S.-C., Lee Y. H. Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis. Clinical Rheumatology. 2012;31:1733–1739.
    1. Raczkiewicz A., Kisiel B., Kulig M., Tlustochowicz W. Vitamin D status and its association with quality of life, physical activity, and disease activity in rheumatoid arthritis patients. Journal of Clinical Rheumatology. 2015;21
    1. Lee Y. H., Bae S. C. Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis. Clinical and Experimental Rheumatology. 2016;34:827–833.
    1. Cutolo M., Otsa K., Laas K., et al. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clinical and Experimental Rheumatology. 2006;24:702–704.
    1. Grazio S., Naglić Đ. B., Anić B., et al. Vitamin D serum level, disease activity and functional ability in different rheumatic patients. The American Journal of the Medical Sciences. 2015;349(1):46–49. doi: 10.1097/maj.0000000000000340.
    1. Brance M. L., Brun L. R., Lioi S., Sánchez A., Abdala M., Oliveri B. Vitamin D levels and bone mass in rheumatoid arthritis. Rheumatology International. 2015;35(3):499–505. doi: 10.1007/s00296-014-3071-6.
    1. Sharma R., Saigal R., Goyal L. K., et al. Estimation of vitamin D levels in rheumatoid arthritis patients and its correlation with the disease activity. The journal of the association of Physicians of India. 2014;62:678–681.
    1. Hong Q., Xu J., Xu S., Lian L., Zhang M., Ding C. Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology. 2014;53(11):1994–2001. doi: 10.1093/rheumatology/keu173.
    1. Gheita T. A., Sayed S., Gheita H. A., Kenawy S. A. Vitamin D status in rheumatoid arthritis patients: relation to clinical manifestations, disease activity, quality of life and fibromyalgia syndrome. International Journal of Rheumatic Diseases. 2014;19:294–299. doi: 10.1111/1756-185X.12426.
    1. Atwa M. A., Balata M. G., Hussein A. M., Abdelrahman N. I., Elminshawy H. H. Serum 25-hydroxyvitamin D concentration in patients with psoriasis and rheumatoid arthritis and its association with disease activity and serum tumor necrosis factor-alpha. Saudi Medical Journal. 2013;34(8):806–813.
    1. Kostoglou-Athanassiou I., Athanassiou P., Lyraki A., Raftakis I., Antoniadis C. Vitamin D and rheumatoid arthritis. Therapeutic Advances in Endocrinology and Metabolism. 2012;3(6):181–187. doi: 10.1177/2042018812471070.
    1. Lin J., Liu J., Davies M. L., Chen W. Vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis. PLoS One. 2016;11e0146351
    1. Wang Y., Zhang F., Wang S., et al. Serum vitamin D level is inversely associated with anti-cyclic citrullinated peptide antibody level and disease activity in rheumatoid arthritis patients. Archives of Rheumatology. 2016;31(1):64–70. doi: 10.5606/ArchRheumatol.2016.5556.
    1. Vojinovic J., Tincani A., Sulli A., et al. European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new patient reported outcome questionnaire (D-PRO) Autoimmunity Reviews. 2017;16(5):548–554. doi: 10.1016/j.autrev.2017.03.002.
    1. Cecchetti S., Tatar Z., Galan P., et al. Prevalence of vitamin D deficiency in rheumatoid arthritis and association with disease activity and cardiovascular risk factors: data from the COMEDRA study. Clinical and Experimental Rheumatology. 2016;34:984–990.
    1. Rajaee E., et al. The relationship between serum level of vitamin D3 and the severity of new onset rheumatoid arthritis activity. Journal of Clinical and Diagnostic Research. 2017;11:Oc28–Oc30. doi: 10.7860/JCDR/2017/24014.9486.
    1. Baykal T., Senel K., Alp F., Erdal A., Ugur M. Is there an association between serum 25-hydroxyvitamin D concentrations and disease activity in rheumatoid arthritis? Bratislava Medical Journal. 2012;113:610–611.
    1. Sahebari M., Mirfeizi Z., Rezaieyazdi Z., Rafatpanah H., Goshyeshi L. 25(OH) vitamin D serum values and rheumatoid arthritis disease activity (DA S28 ESR) Caspian Journal of Internal Medicine. 2014;5:148–155.
    1. Park Y.-E., Kim B.-H., Lee S.-G., et al. Vitamin D status of patients with early inflammatory arthritis. Clinical Rheumatology. 2015;34(2):239–246. doi: 10.1007/s10067-014-2613-3.
    1. Furuya T., Hosoi T., Tanaka E., et al. Prevalence of and factors associated with vitamin D deficiency in 4,793 Japanese patients with rheumatoid arthritis. Clinical Rheumatology. 2013;32(7):1081–1087. doi: 10.1007/s10067-013-2216-4.
    1. Haga H. J., Schmedes A., Naderi Y., Moreno A. M., Peen E. Severe deficiency of 25-hydroxyvitamin D3(25-OH-D3) is associated with high disease activity of rheumatoid arthritis. Clinical Rheumatology. 2013;32(5):629–633. doi: 10.1007/s10067-012-2154-6.
    1. Rossini M., Bongi S. M., la Montagna G., et al. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Research & Therapy. 2010;12(6, article R216) doi: 10.1186/ar3195.
    1. Varenna M., Manara M., Cantatore F. P., et al. Determinants and effects of vitamin D supplementation on serum 25-hydroxy-vitamin D levels in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology. 2012;30:714–719.
    1. Sainaghi P. P., Bellan M., Carda S., et al. Hypovitaminosis D and response to cholecalciferol supplementation in patients with autoimmune and non-autoimmune rheumatic diseases. Rheumatology International. 2012;32(11):3365–3372. doi: 10.1007/s00296-011-2170-x.
    1. Mouyis M., Ostor A. J., Crisp A. J., Ginawi A., Halsall D. J., Shenker N. Hypovitaminosis D among rheumatology outpatients in clinical practice. Rheumatology. 2008;47(9):1348–1351. doi: 10.1093/rheumatology/ken203.
    1. Stoll D., Dudler J., Lamy O., et al. High prevalence of hypovitaminosis D in a Swiss rheumatology outpatient population. Swiss Medical Weekly. 2011;141 doi: 10.4414/smw.2011.13196.w13196
    1. Hajjaj-Hassouni N., Mawani N., Allali F., et al. Evaluation of vitamin D status in rheumatoid arthritis and its association with disease activity across 15 countries: 'the comora study'. International Journal of Rheumatology. 2017;2017:8. doi: 10.1155/2017/5491676.5491676
    1. Azzeh F. S., Kensara O. A. Vitamin D is a good marker for disease activity of rheumatoid arthritis disease. Disease Markers. 2015;2015:6. doi: 10.1155/2015/260725.260725
    1. Nakamura Y., Suzuki T., Yoshida T., Yamazaki H., Kato H. Vitamin d and calcium are required during denosumab treatment in osteoporosis with rheumatoid arthritis. Nutrients. 2017;9(5)
    1. Lo Gullo A., Mandraffino G., Bagnato G., et al. Vitamin D status in rheumatoid arthritis: inflammation, arterial stiffness and circulating progenitor cell number. PLoS ONE. 2015;10(8) doi: 10.1371/journal.pone.0134602.e0134602
    1. Bansal A. S., Henriquez F., Sumar N., Patel S. Thelper cell subsets in arthritis and the benefits of immunomodulation by 1,25(OH) 2 vitamin D. Rheumatology International. 2012;32(4):845–852. doi: 10.1007/s00296-011-2077-6.
    1. Van Hamburg J. P., Asmawidjaja P. S., Davelaar N., et al. TNF blockade requires 1,25(OH) 2D 3to control human Th17-mediated synovial inflammation. Annals of the Rheumatic Diseases. 2012;71(4):606–612. doi: 10.1136/annrheumdis-2011-200424.
    1. Liu Y., Wen H. Impact of vitamin deficiency on clinical parameters in treatment-na∩ve rheumatoid arthritis patients. Zeitschrift für Rheumatologie. 2018;77:833–840.
    1. Bragazzi N. L., Watad A., Neumann S. G., et al. Vitamin D and rheumatoid arthritis: an ongoing mystery. Current Opinion in Rheumatology. 2017;29(4):378–388. doi: 10.1097/BOR.0000000000000397.
    1. Maruotti N., Cantatore F. P. Vitamin D and the immune system. The Journal of Rheumatology. 2010;37:p. 491.
    1. Adami G., Rossini M., Bogliolo L., et al. An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis. Modern Rheumatology. 2018:1–4. doi: 10.1080/14397595.2018.1532622.
    1. Pu D., Luo J., Wang Y., et al. Prevalence of depression and anxiety in rheumatoid arthritis patients and their associations with serum vitamin D level. Clinical Rheumatology. 2018;37(1):179–184. doi: 10.1007/s10067-017-3874-4.
    1. Yesil H., Sungur U., Akdeniz S., Gurer G., Yalcin B., Dundar U. Association between serum vitamin D levels and neuropathic pain in rheumatoid arthritis patients: a cross-sectional study. International Journal of Rheumatic Diseases. 2018;21(2):431–439. doi: 10.1111/1756-185X.13160.
    1. Mateen S., Moin S., Shahzad S., Khan A. Q. Level of inflammatory cytokines in rheumatoid arthritis patients: Correlation with 25-hydroxy vitamin D and reactive oxygen species. Plos One. 2017;12e0178879
    1. Tan L.-M., Long T.-T., Guan X.-L., et al. Diagnostic value of vitamin D status and bone turnover markers in rheumatoid arthritis complicated by osteoporosis. Annals of Clinical and Laboratory Science. 2018;48:197–204.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit